The role of the human papillomavirus (HPV) vaccine in developing countries

International Journal of Dermatology

Volumn 49, Issue 4, 2010, Pages 377-379

  Kling, Max ^a   Zeichner, Joshua A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SURVIVAL RATE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS RESISTANCE;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WORLD HEALTH;

EID: 77952006801     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04316.x     Document Type: Review

References (20)

1. Barnabas RV, Garnett GP. The potential public health impact of vaccines against human papillomavirus. The Clinical Handbook of Human Papillomavirus 2004, Prendivill W, Davies P. In, eds, Lancaster, United Kingdom, Parthenon Publishing/Parthenon Medical Communications
2. Projects of mortality and burden of disease. http://www.who.int/healthinfo/global_burden_disease/en/index.htm, Accessed March 15, 2009.
3. Parkin DM, Bray F. Chapter 2: The Burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S11-S25.
4. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med 2007, 356:1908-1910.
5. zur Hausen H. Infections Causing Human Cancer 2006, 1-16. Weinheim, WILEY-VCH Verlag GmbH & Co. KGaA
6. Altman Lawrence K. Discovery of AIDS and cancer viruses win Nobel. NY Times 2008, October 7
7. Munoz N, Bosch FX, Castellsague X. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 1111:278-285.
8. Katz IT, Wright AA. Preventing cervical cancer n the developing world. N Engl J Med 2006, 354:1110.
9. Peto J, Gilham C, Fletcher O. The cervical cancer epidemic that screening has prevented. Lancet 2004, 364:29-56.
10. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average level and large inequalities. Policy Forum 2008 Accessed: March 15, 2009
11. Goldie SJ, Gaffikin L, Goldhaber-Fiebert DD. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005, 353:2158-2168.
12. Gardasil. Prescribing Information 2006, Whitehouse Station, NJ, Merck and Co, Inc.
13. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
14. Saslow D, Castle PE, Cox JT. American Cancer Society guidelines for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7-28.
15. The global alliance for vaccines and immunization. http://www.gavialliance.org, Accessed March 15, 2009.
16. Dasbach EJ, Elbasha EH, RP Insinga. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillommavirus infection and disease. Epidemiol Rev 2006, 28:88-100.
17. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
18. Haug C. Human papillomavirus vaccination - reasons for caution. N Engl J Med 2008, 359:861-862.
19. Villa LL, Costa RL, Petta CA. Duration of immunicity - high sustained efficacy of a prophylactic quadrivalent human papilloma virus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
20. GAVI alliance: new vaccine strategy prioritises deadly diseases meningococcal Japanese encephalitis and cervical cancer among those identified. http://www.maximsnews.com/news20080718gaviallncevaccinationprioritisation10807181604.htm, Accessed March 15, 2009.